Ethic Inc. Sells 8,298 Shares of Johnson & Johnson (NYSE:JNJ)

Ethic Inc. lessened its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 37.4% in the first quarter, HoldingsChannel.com reports. The fund owned 13,879 shares of the company’s stock after selling 8,298 shares during the period. Ethic Inc.’s holdings in Johnson & Johnson were worth $2,460,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after purchasing an additional 3,358,478 shares in the last quarter. BlackRock Inc. boosted its stake in Johnson & Johnson by 0.4% in the first quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock valued at $35,587,638,000 after buying an additional 777,837 shares in the last quarter. State Street Corp grew its position in Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after acquiring an additional 2,492,359 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock worth $7,576,867,000 after acquiring an additional 1,084,834 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Johnson & Johnson by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock valued at $5,683,837,000 after purchasing an additional 509,818 shares in the last quarter. Institutional investors and hedge funds own 68.59% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $165.71 on Friday. The company has a market capitalization of $435.68 billion, a PE ratio of 24.12, a P/E/G ratio of 3.15 and a beta of 0.61. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. The company has a 50 day simple moving average of $170.32 and a two-hundred day simple moving average of $174.25.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. Johnson & Johnson’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.48 earnings per share. Research analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.73%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research reports. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating for the company. SVB Leerink cut their price objective on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. UBS Group reduced their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, July 8th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.